(kwih-ZAR-tih-nib dy-HY-droh-KLOR-ide)
This page contains brief information about quizartinib dihydrochloride and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Quizartinib dihydrochloride is approved to treat:
- Acute myeloid leukemia that is newly diagnosed and has a certain mutation in the FLT3 gene. It is used in adults, first with cytarabine and an anthracycline drug as induction therapy, next with cytarabine as consolidation therapy, and then alone as maintenance therapy.
Quizartinib dihydrochloride is only available as part of a special program called Vanflyta REMS (Risk Evaluation and Mitigation Strategies).
More About Quizartinib Dihydrochloride
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Quizartinib Dihydrochloride – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Quizartinib Approval Adds New Treatment Option for AML, Including in Older Patients
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Quizartinib Dihydrochloride – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
